{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:36:52Z","timestamp":1791297412696,"version":"4.1.0"},"reference-count":102,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease involving several articular and extra-articular structures. Despite the important progresses recently made in all of the aspects of this disease, its management is still burdened by unresolved issues. The aim of this exercise was to provide a set of statements that may be helpful for the management of PsA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A group of 38 Italian rheumatologists with recognized expertise in PsA selected and addressed the following four topics: \u201cearly PsA,\u201d \u201caxial-PsA,\u201d \u201cextra-articular manifestations and comorbidities,\u201d \u201ctherapeutic goals.\u201d Relevant articles from the literature (2016\u20132022) were selected by the experts based on a PubMed search. A number of statements for each topic were elaborated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ninety-four articles were selected and evaluated, 68 out of the 1,114 yielded by the literature search and 26 added by the Authors. Each of the four topic was subdivided in themes as follows: transition from psoriasis to PsA, imaging vs. CASPAR criteria in early diagnosis, early treatment for \u201cearly PsA\u201d; axial-PsA vs. axialspondyloarthritis, diagnosis, clinical evaluation, treatment, standard radiography vs. magnetic resonance imaging for \u201caxial PsA\u201d; influence of inflammatory bowel disease on the therapeutic choice, cardiovascular comorbidity, bone damage, risk of infection for \u201ccomorbidities and extra-articular manifestations\u201d; target and tools, treat-to-target strategy, role of imaging for \u201ctherapeutic goals.\u201d The final document consisted of 49 statements.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The final product of this exercise is a set of statements concerning the main issues of PsA management offering an expert opinion for some unmet needs of this complex disease.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1327931","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T09:26:35Z","timestamp":1701422795000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Management of psoriatic arthritis: a consensus opinion by expert rheumatologists"],"prefix":"10.3389","volume":"10","author":[{"given":"Salvatore","family":"D\u2019Angelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Benucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerolamo","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Cantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Felice","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Caso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ciccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Dejaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar Massimiliano","family":"Epis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Fusaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gabini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gerli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Govoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Gremese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Guggino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Iagnocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlomaurizio","family":"Montecucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Peluso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Ramonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Domenico","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Selmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Tirri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marchesoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","article-title":"The psychosocial burden of psoriatic arthritis","volume":"47","author":"Husni","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3899\/jrheum.180670","article-title":"Burden and disease characteristics of patients with psoriatic arthritis: a population-based cross-sectional study","volume":"46","author":"Tekin","year":"2019","journal-title":"J Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"5677","DOI":"10.1093\/rheumatology\/keab233","article-title":"The burden of psoriatic arthritis in the biologics era: data from the Belgian epidemiological psoriatic arthritis study","volume":"60","author":"de Vlam","year":"2021","journal-title":"Rheumatology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3899\/jrheum.210963","article-title":"Is psoriatic arthritis associated with higher risk of mortality?","volume":"49","author":"Leung","year":"2022","journal-title":"J Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41584-022-00776-6","article-title":"Psoriatic arthritis from a mechanistic perspective","volume":"18","author":"Schett","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41584-022-00874-5","article-title":"Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy","volume":"19","author":"Najm","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"101670","DOI":"10.1016\/j.berh.2021.101670","article-title":"Clinical features of psoriatic arthritis","volume":"35","author":"Kishimoto","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e002934","DOI":"10.1136\/rmdopen-2022-002934","article-title":"Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-na\u00efve population of patients with PsA","volume":"9","author":"Richette","year":"2023","journal-title":"RMD Open"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1093\/rheumatology\/keac078","article-title":"Defining imaging sub-phenotypes of psoriatic arthritis: integrative analysis of imaging data and gene expression in a PsA patient cohort","volume":"61","author":"Eder","year":"2022","journal-title":"Rheumatology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e001728","DOI":"10.1136\/rmdopen-2021-001728","article-title":"Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study","volume":"7","author":"L\u00f3pez-Medina","year":"2021","journal-title":"RMD Open"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e002074","DOI":"10.1136\/rmdopen-2021-002074","article-title":"Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes","volume":"8","author":"McInnes","year":"2022","journal-title":"RMD Open"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"101693","DOI":"10.1016\/j.berh.2021.101693","article-title":"Unmet needs in psoriatic arthritis","volume":"35","author":"Ng","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","article-title":"Delphi methodology in healthcare research: how to decide its appropriateness","volume":"11","author":"Nasa","year":"2021","journal-title":"World J Methodol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.5114\/ada.2020.100478","article-title":"Pathogenesis of psoriasis in the \"omic\" era. Part IV. Epidemiology, genetics, immunopathogenesis, clinical manifestation and treatment of psoriatic arthritis","volume":"37","author":"Szczerkowska-Dobosz","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/art.41652","article-title":"Tissue-resident memory CD8+ T cells from skin differentiate psoriatic arthritis from psoriasis","volume":"73","author":"Leijten","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3389\/fimmu.2018.01550","article-title":"The initiation, but not the persistence, of experimental spondyloarthritis is dependent on Interleukin-23 signaling","volume":"9","author":"van Tok","year":"2018","journal-title":"Front Immunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"723944","DOI":"10.3389\/fmed.2021.723944","article-title":"Early origins of psoriatic arthritis: clinical, genetic and molecular biomarkers of progression from psoriasis to psoriatic arthritis","volume":"8","author":"Pennington","year":"2021","journal-title":"Front Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.3390\/biomedicines10102387","article-title":"Omics and multi-omics analysis for the early identification and improved outcome of patients with psoriatic arthritis","volume":"10","author":"Gurke","year":"2022","journal-title":"Biomedicine"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3390\/ijms19020530","article-title":"Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints","volume":"19","author":"Boutet","year":"2018","journal-title":"Int J Mol Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/imr.12840","article-title":"Interleukin-23 pathway at the enthesis: the emerging story of enthesitis in spondyloarthropathy","volume":"294","author":"Bridgewood","year":"2020","journal-title":"Immunol Rev"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/art.41239","article-title":"Association of Structural Entheseal Lesions with an increased risk of progression from psoriasis to psoriatic arthritis","volume":"74","author":"Simon","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"vi38","DOI":"10.1093\/rheumatology\/keab504","article-title":"Integrating imaging and biomarker assessment to better define psoriatic arthritis and predict response to biologic therapy","volume":"60","author":"Elliott","year":"2021","journal-title":"Rheumatology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1080\/09546634.2021.1942423","article-title":"A clinical perspective on risk factors and signs of subclinical and early psoriatic arthritis among patients with psoriasis","volume":"33","author":"Gottlieb","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"532","DOI":"10.55563\/clinexprheumatol\/ert0p7","article-title":"Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: cross-sectional data from the psoriatic arthritis-international database","volume":"39","author":"Bilgin","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41584-021-00578-2","article-title":"Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study","volume":"17","author":"Perez-Chada","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"151949","DOI":"10.1016\/j.semarthrit.2021.12.013","article-title":"Time to transition from psoriasis to psoriatic arthritis: a population-based study","volume":"52","author":"Karmacharya","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11926-020-00891-x","article-title":"From psoriasis to psoriatic arthritis: insights from imaging on the transition to psoriatic arthritis and implications for arthritis prevention","volume":"22","author":"Zabotti","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s40744-021-00378-w","article-title":"Predictors, risk factors, and incidence rates of psoriatic arthritis development in psoriasis patients: a systematic literature review and Meta-analysis","volume":"8","author":"Zabotti","year":"2021","journal-title":"Rheumatol Ther"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.semarthrit.2021.01.008","article-title":"Measurement properties of radiographic outcome measures in psoriatic arthritis: a systematic review from the GRAPPA-OMERACT initiative","volume":"51","author":"Antony","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"935132","DOI":"10.3389\/fimmu.2022.935132","article-title":"Improved diagnostic performance of CASPAR criteria with integration of ultrasound","volume":"13","author":"Geng","year":"2022","journal-title":"Front Immunol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13244-021-01035-0","article-title":"Role of diagnostic imaging in psoriatic arthritis: how, when, and why","volume":"12","author":"Crespo-Rodr\u00edguez","year":"2021","journal-title":"Insights Imaging"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"551684","DOI":"10.3389\/fmed.2020.551684","article-title":"Recent advances in imaging for diagnosis, monitoring, and prognosis of psoriatic arthritis","volume":"7","author":"Fassio","year":"2020","journal-title":"Front Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13075-020-2103-8","article-title":"Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research","volume":"22","author":"van der Heijde","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13075-019-1957-0","article-title":"Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study","volume":"21","author":"Kampylafka","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1136\/annrheumdis-2020-218186","article-title":"IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors","volume":"80","author":"Nerviani","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1080\/14712598.2020.1737855","article-title":"Role of the IL-23 pathway in the pathogenesis and treatment of enthesitis in psoriatic arthritis","volume":"20","author":"Rossini","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13555-021-00650-5","article-title":"Arthritis interception in patients with psoriasis treated with Guselkumab","volume":"12","author":"Zabotti","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.3390\/jcm11072051","article-title":"Diagnosis and intervention in early psoriatic arthritis","volume":"11","author":"Hioki","year":"2022","journal-title":"J Clin Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e063650","DOI":"10.1136\/bmjopen-2022-063650","article-title":"Efficacy of guselkumab, a selective IL-23 inhibitor, in preventing arthritis in a multicentre psoriasis at-risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial","volume":"12","author":"Haberman","year":"2022","journal-title":"BMJ Open"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11926-021-00999-8","article-title":"Axial psoriatic arthritis","volume":"23","author":"Gladman","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41584-018-0006-8","article-title":"Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison","volume":"14","author":"Feld","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/rheumatology\/kez457","article-title":"Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?","volume":"59","author":"Feld","year":"2020","journal-title":"Rheumatology"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.semarthrit.2021.06.006","article-title":"Axial involvement in psoriatic arthritis: an update for rheumatologists","volume":"51","author":"Poddubnyy","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e002513","DOI":"10.1136\/rmdopen-2022-002513","article-title":"Characterising the axial phenotype of psoriatic arthritis: a study comparing axial psoriatic arthritis and ankylosing spondylitis with psoriasis from the REGISPONSER registry","volume":"8","author":"Michelena","year":"2022","journal-title":"RMD Open"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.semarthrit.2021.04.018","article-title":"Unveiling axial involvement in psoriatic arthritis: an ancillary analysis of the ASAS-perSpA study","volume":"51","author":"Benavent","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1759720X20971889","DOI":"10.1177\/1759720X20971889","article-title":"Axial spondyloarthritis and axial psoriatic arthritis: similar or different disease spectrum?","volume":"12","author":"Benavent","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.semarthrit.2021.03.007","article-title":"Axial disease in psoriatic arthritis: the presence and progression of unilateral grade 2 sacroiliitis in a psoriatic arthritis cohort","volume":"51","author":"Feld","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.3390\/jcm10132845","article-title":"Axial psoriatic disease: clinical and imaging assessment of an underdiagnosed condition","volume":"10","author":"Giovannini","year":"2021","journal-title":"J Clin Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2020.05.089","article-title":"Axial psoriatic arthritis: an update for dermatologists","volume":"84","author":"Gottlieb","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1759720X211057975","DOI":"10.1177\/1759720X211057975","article-title":"Axial involvement in psoriatic arthritis cohort (AXIS): the protocol of a joint project of the assessment of SpondyloArthritis international society (ASAS) and the Group for Research and Assessment of psoriasis and psoriatic arthritis (GRAPPA)","volume":"13","author":"Poddubnyy","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.55563\/clinexprheumatol\/8zn9z8","article-title":"Axial psoriatic arthritis and ankylosing spondylitis: same or different? A real-world study with emphasis on comorbidities","volume":"40","author":"Fragoulis","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejr.2021.07.006","article-title":"Comparative analysis between ankylosing spondylitis and axial psoriatic arthritis patients","volume":"44","author":"Abdelaziz","year":"2022","journal-title":"Egypt. Rheumatol."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"142","DOI":"10.31138\/mjr.33.1.142","article-title":"Axial disease in psoriatic arthritis: how can we define it, and does it have an impact on treatment?","volume":"33","author":"Lopez-Medina","year":"2022","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"e715","DOI":"10.1016\/S2665-9913(21)00105-3","article-title":"Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies","volume":"3","author":"Mease","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1186\/s13063-022-06589-y","article-title":"Efficacy and safety of guselkumab in biologic-na\u00efve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial","volume":"23","author":"Gladman","year":"2022","journal-title":"Trials"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of Ustekinumab in axial Spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"iv28","DOI":"10.1093\/rheumatology\/keab617","article-title":"IL-23 and axial disease: do they come together?","volume":"60","author":"Mease","year":"2021","journal-title":"Rheumatology"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/rheumatology\/key069","article-title":"Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis","volume":"58","author":"Miyagawa","year":"2019","journal-title":"Rheumatology"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3899\/jrheum.220309","article-title":"Management of axial disease in patients with psoriatic arthritis: an updated literature review informing the 2021 GRAPPA treatment recommendations","volume":"50","author":"Lubrano","year":"2023","journal-title":"J Rheumatol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","article-title":"Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial","volume":"80","author":"Baraliakos","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"700.1","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00296-020-04775-2","article-title":"Comorbidities in psoriatic arthritis: a systematic review and meta-analysis","volume":"41","author":"Gupta","year":"2021","journal-title":"Rheumatol Int"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1093\/rheumatology\/keaa780","article-title":"Comorbidities, pain and fatigue in psoriatic arthritis, psoriasis and healthy controls: a clinical cohort study","volume":"60","author":"Ballegaard","year":"2021","journal-title":"Rheumatology"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.3389\/fimmu.2018.01390","article-title":"T cell hierarchy in the pathogenesis of psoriasis and associated cardiovascular comorbidities","volume":"9","author":"Casciano","year":"2018","journal-title":"Front Immunol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1093\/rheumatology\/keab655","article-title":"Cardiovascular disease in psoriatic arthritis: facts and unmet needs","volume":"61","author":"Gialouri","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1093\/rheumatology\/keaa025","article-title":"Treat to target and prevention of subclinical atherosclerosis in psoriatic arthritis-which target should we choose?","volume":"59","author":"Cheng","year":"2020","journal-title":"Rheumatology"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1111\/jdv.16273","article-title":"The role of the interleukin-23\/Th17 pathway in cardiometabolic comorbidity associated with psoriasis","volume":"34","author":"Egeberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"742713","DOI":"10.3389\/fmed.2021.742713","article-title":"Update on cardiovascular risk and obesity in psoriatic arthritis","volume":"8","author":"Ram\u00edrez","year":"2021","journal-title":"Front Med"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"108397","DOI":"10.1016\/j.clim.2020.108397","article-title":"Comorbidities associated with psoriatic arthritis: review and update","volume":"214","author":"Perez-Chada","year":"2020","journal-title":"Clin Immunol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"735150","DOI":"10.3389\/fmed.2021.735150","article-title":"Psoriatic arthritis and metabolic syndrome: is there a role for disease modifying anti-rheumatic drugs?","volume":"8","author":"Atzeni","year":"2021","journal-title":"Front Med"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"6648","DOI":"10.3390\/ijms23126648","article-title":"Killing two birds with one stone: potential therapies targeting psoriasis and atherosclerosis at the same time","volume":"23","author":"Merzel \u0160abovi\u0107","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"3159283","DOI":"10.1155\/2019\/3159283","article-title":"Arterial hypertension and interleukins: potential therapeutic target or future diagnostic marker?","volume":"2019","author":"Tanase","year":"2019","journal-title":"Int J Hypertens"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.14309\/crj.2018.56","article-title":"Rapid onset of inflammatory bowel disease after receiving secukinumab infusion","volume":"5","author":"Wang","year":"2018","journal-title":"ACG Case Rep J"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"9679287","DOI":"10.1155\/2018\/9679287","article-title":"A challenging case of severe ulcerative colitis following the initiation of secukinumab for ankylosing spondylitis","volume":"2018","author":"Ehrlich","year":"2018","journal-title":"Case Rep Gastrointest Med"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41395-018-0422-z","article-title":"New onset of inflammatory bowel disease in three patients undergoing IL-17A inhibitor secukinumab: a case series","volume":"114","author":"Vernero","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D'Haens","year":"2022","journal-title":"Lancet"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the treatment of Crohn's disease: induction results from the phase 2 GALAXI-1 study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41575-022-00589-8","article-title":"Gasdermin B in IBD and epithelial barrier repair","volume":"19","author":"Hindson","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1136\/annrheumdis-2020-217092","article-title":"Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020","volume":"79","author":"Lortholary","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/annrheumdis-2019-216102","article-title":"Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis","volume":"79","author":"Li","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1002\/acr.24630","article-title":"Risk of hospitalization for serious infection after initiation of ustekinumab or other biologics in patients with psoriasis or psoriatic arthritis","volume":"74","author":"Jin","year":"2022","journal-title":"Arthritis Care Res"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40744-018-0132-4","article-title":"Assessing disease activity in psoriatic arthritis: a literature review","volume":"6","author":"Tucker","year":"2019","journal-title":"Rheumatol Ther."},{"key":"ref86","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.3390\/jcm9103103","article-title":"Patient-centered care in psoriatic arthritis-a perspective on inflammation, disease activity, and psychosocial factors","volume":"9","author":"Batko","year":"2020","journal-title":"J Clin Med"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1002\/msc.1692","article-title":"Outcome measures in psoriatic arthritis: where next?","volume":"20","author":"Hackett","year":"2022","journal-title":"Musculoskeletal Care"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3899\/jrheum.180267","article-title":"What should be the primary target of \"treat to target\" in psoriatic arthritis?","volume":"46","author":"Coates","year":"2019","journal-title":"J Rheumatol"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"5659","DOI":"10.3390\/jcm10235659","article-title":"Implementation of the treat-to-target concept in evaluation of psoriatic arthritis patients","volume":"10","author":"Gazitt","year":"2021","journal-title":"J Clin Med"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"e001002","DOI":"10.1136\/rmdopen-2019-001002","article-title":"Measurement properties of the minimal disease activity criteria for psoriatic arthritis","volume":"5","author":"Coates","year":"2019","journal-title":"RMD Open"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"105296","DOI":"10.1016\/j.jbspin.2021.105296","article-title":"Inconsistencies of the disease activity assessment tools for psoriatic arthritis: challenges to rheumatologists","volume":"89","author":"Gezer","year":"2022","journal-title":"Joint Bone Spine"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"e001083","DOI":"10.1136\/rmdopen-2019-001083","article-title":"Treat-to-target in PsA: methods and necessity","volume":"6","author":"Dures","year":"2020","journal-title":"RMD Open"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.semarthrit.2019.06.001","article-title":"Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: a systematic review and network meta-analysis","volume":"49","author":"Lu","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11926-018-0781-x","article-title":"Novel concepts in psoriatic arthritis management: can we treat to target?","volume":"20","author":"Tucker","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1136\/annrheumdis-2020-217163","article-title":"Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1136\/annrheumdis-2022-222260","article-title":"Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial","volume":"81","author":"Michielsens","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1093\/rheumatology\/keab741","article-title":"Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study","volume":"61","author":"Michielsens","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13063-019-4000-5","article-title":"Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial","volume":"21","author":"Michielsens","year":"2020","journal-title":"Trials"},{"key":"ref99","first-page":"573","article-title":"Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies errata","volume":"19","author":"Gottlieb","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1093\/rheumatology\/keab119","article-title":"Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis","volume":"60","author":"Mease","year":"2021","journal-title":"Rheumatology"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/acr.24538","article-title":"Prevalence and factors associated with osteoporosis and bone mineral density testing in psoriatic arthritis","volume":"74","author":"Kwok","year":"2022","journal-title":"Arthritis Care Res"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1136\/annrheumdis-2020-217892","article-title":"Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study","volume":"79","author":"Xia","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1327931\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T09:26:39Z","timestamp":1701422799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1327931\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":102,"alternative-id":["10.3389\/fmed.2023.1327931"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1327931","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]},"article-number":"1327931"}}